Vertex Pharmaceuticals

Open: 361.46 Close: 365.25 Change: 3.79

The stock market through the eyes of an AI: Vertex Pharmaceuticals Company Inc Stock.

This document will help you to evaluate Vertex Pharmaceuticals without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, financial, market, VRTX, stock, company, …

Concept Map

Semantic Network

Stock Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with.

Today's Summary

Vertex develops therapies to address cystic fibrosis and other diseases. The biotechnology company is rated a Buy.

Today's News

Vertex Pharmaceuticals Inc. stock rises wed Wednesday, outperforms market - marketwatch.com. Investors should keep an eye on any recent revisions to analyst forecasts for Vertex. The biotechnology company develops therapies to address cystic fibrosis. Vertex Pharmaceuticals Incorporated (VRTX) will report its third quarter 2023 financial results on Monday, November 6, 2023 after the financial markets close. Vertex develops therapies to address cystic fibrosis and other diseases. Vertex Pharmaceuticals (NASDAQ:VRTX) is rated a Buy. The stock price of VRTX is 365.25 USD today. Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report ) last posted its quarterly earnings data on Tuesday, August 1st. The company is expected to post 13.26 EPS for the current fiscal year. The stock price for Vertex Pharmaceuticals ( NASDAQ : VRTX ) is $ 365.25 last updated October 11, 2023 at 8:11 PM UTC. The latest price target for the company was reported by Morgan Stanley on Monday, October 9, 20 23. Suketu Upadhyay elected to Vertexs board of directors as an independent director. Vertex to announce third quarter 2023 financial results on November 6, 2023 after the financial markets close. European Medicines Agencies Agencies. for Medicinal Products for Human Use (CHMP) adopted a p... 26 days ago - Business Wire Vertex Researchers Awarded 2024 Breakthrough Prize in Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on August 1, 2023 after the financial markets close. The first glimpse of that future could come in early December, when the FDA is set to decide on approval for sickle cell treatment. Vertex Pharmaceuticals recently partnered with Lonza Group on June 6, 2023. Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies. Vertex Pharmaceuticals announced clinical trial clearances from both the FDA and Health Canada for our investigational encapsulated cell therapy for the potential treatment of type 1 diabetes. CEO Reshma Kewalramani, MD FASN, received the 2023 Distinguished Alumni Award.

Stock Profile

"Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts."

Keywords

Are looking for the most relevant information about Vertex Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Vertex Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Vertex Pharmaceuticals are: Vertex, Pharmaceuticals, financial, market, VRTX, stock, company, and the most common words in the summary are: vertex, pharmaceutical, stock, market, vrtx, best, price, . One of the sentences in the summary was: Vertex develops therapies to address cystic fibrosis and other diseases. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #vertex #pharmaceutical #stock #market #vrtx #best #price.